Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
10 hedge funds and large institutions have $110K invested in Genetic Technologies Ltd. in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
60% less capital invested
Capital invested by funds: $274K → $110K (-$164K)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$21.5K |
| 2 |
Citigroup
New York
|
+$1.2K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$239 |
| 4 |
CIM
Calvert Investment Management
Bethesda,
Maryland
|
+$239 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$42.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$33.4K |
| 3 |
Morgan Stanley
New York
|
-$32.4K |
| 4 |
U
UBS
Zurich,
Switzerland
|
-$14K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$10.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
1
Virtu KCG Holdings
New York
| $27K | -$42.4K | -355 | -58% |
|
|
2
Citadel Advisors
Miami,
Florida
| $20K | -$33.4K | -279 | -60% |
|
|
3
Renaissance Technologies
New York
| $19K | +$21.5K | +180 | New |
|
|
ARTA
4
A.R.T. Advisors
New York
| $14K | -$2.15K | -18 | -12% |
|
|
APU
5
Alpine Partners USVI
St. Thomas,
U.S. Virgin Islands
| $12K | – | – | – |
|
|
CIM
6
Calvert Investment Management
Bethesda,
Maryland
| $11K | +$239 | +2 | +2% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $4K | -$10.3K | -86 | -67% |
|
|
8
Citigroup
New York
| $2K | +$1.2K | +10 | +200% |
|
9
Group One Trading
Chicago,
Illinois
| $1K | -$598 | -5 | -33% |
|
|
10
Morgan Stanley
New York
| – | -$32.4K | -271 | Closed |
|
|
U
11
UBS
Zurich,
Switzerland
| – | -$14K | -100 | Closed |
|
|
12
Ameriprise
Minneapolis,
Minnesota
| – | +$239 | +2 | New |
|
GENE Hedge Fund Activity: Q2 2014 in Review
10 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q2 2014, worth a combined $110K — down 60% from $274K a quarter earlier.
Fund positioning in GENE was balanced in Q2 2014: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $21.5K. The largest seller was Virtu KCG Holdings, cutting an estimated $42.4K.
- 10 institutional investors held Genetic Technologies Ltd. (GENE) as of Q2 2014, unchanged from Q1 2014.
- Funds reported $110K of Genetic Technologies Ltd. stock for Q2 2014, down 60% quarter-over-quarter.
- 2 funds opened new Genetic Technologies Ltd. positions in Q2 2014 and 2 closed out, a net change of 0 holders.
- The largest Genetic Technologies Ltd. buyer in Q2 2014 was Renaissance Technologies, an estimated $21.5K added.
- The largest Genetic Technologies Ltd. seller in Q2 2014 was Virtu KCG Holdings, an estimated $42.4K sold.
Based on aggregated 13F filings for Q2 2014.